Skip to Content

Melflufen is Safe and Effective in Patients with Alkylator-Refractory Disease

This recent study evaluated the efficacy of melflufen-dex compared to pomalidomide-dex in patients with multiple myeloma who are refractory to alkylators. The trial’s results contributed to the approval of melflufen-dex in Europe for patients who have undergone at least three previous lines of treatment, including those who have not undergone a transplant or did not progress after a transplant within three years.

Fredrik Hellem Schjesvold

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top